Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
OwnerPaul Gavarisinventor
Life of this patent
Estimating the term…
Abstract
An ophthalmic treatment composition for the treatment of dry eye consists essentially of squalane in an amount by weight of 1% to 100%; and mineral oil in an amount by weight of 0% to 99%. Preferably, the mineral oil is a light mineral oil or mixture of light mineral oils and is present in an amount by weight of 1% to 10%. The composition is effectively devoid of water, preservatives, emulsifiers and dispersing agents. A related ophthalmic treatment composition comprises squalane in an amount by weight of 1% to 99% and mineral oil in an amount by weight of 0% to 99% and at least one hydrophobic or lipophilic pharmaceutical substance in an amount by weight of 0.01% to 5%, effective for treatment of at least one ophthalmic condition.
Claims14
An ophthalmic treatment composition consisting essentially of squalane in an amount of at least 80% volume/volume;
- and a mineral oil or mixture of mineral oils in an amount of 0% to 20% volume/volume, wherein the squalane inhibits dry eye, the composition being effectively devoid of water, preservatives, emulsifiers and dispersing agents.
(canceled)
5-10. (canceled)
A method for treating keratoconjunctivitis sicca in a mammal in need thereof consisting of administering to said mammal in need thereof therapeutically effective amounts of a composition comprising squalane, wherein the squalane inhibits dry eye, the composition including squalane in an amount of at least 80% volume/volume, the composition being effectively devoid of water, preservatives, emulsifiers and dispersing agents.
14-20. (canceled)
A delivery vehicle or carrier for use in the manufacture of an ophthalmic medicament or treatment composition containing a hydrophobic or lipophilic pharmaceutical therapeutic agent, comprising squalane in an amount of at least 80% volume/volume and an amount of mineral oil no greater than that necessary to solubilize the hydrophobic or lipophilic pharmaceutical therapeutic agent.
The composition defined in claim 5 wherein the mineral oil or mixture of mineral oils is present in an amount no greater than that necessary to solubilize the at least one hydrophobic or lipophilic pharmaceutical substance.
The composition defined in claim 5 wherein the composition includes squalane in an amount of at least 90% volume/volume.
Dependencies are inferred from the claim text.